Forgot your password ?

 login: 

  Why you need to be registered

 password: 

 Register 

Current issueArchivesubscribeInstructions to Authors

search by
Google





subscribe on the news  

 

Pay Color Illustration
 


Medline

PubMed, a service of the National Library of Medicine

World Oncology Network

R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology



Vol. 31, No. 4, 2009 (December)

Content

Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer

 

R. Krupa1, T. Sliwinski2, Z. Morawiec3, E. Pawlowska4, M. Zadrozny5, J. Blasiak2

1. Laboratory of DNA Repair, Department of Molecular Genetics, University of Lodz, Lodz 90-237, Poland 2. Department of Molecular Genetics, University of Lodz, Lodz 90-237, Poland 3. N. Copernicus Hospital, Lodz 93-510, Poland 4. Department of Pediatric Dentistry, Medical University of Lodz, Lodz 92-216, Poland 5. Polish Mother̓s Memorial Hospital, Lodz 93-338, Poland

Abstract. A C/T transition — rs4987117 (the Thr1915Met polymorphism) and an A/G transition — rs11571653 (the Met784Val polymorphism) in the BRCA2 gene were linked to breast cancer risk in Polish and Japanese populations, respectively. Aim: To study the association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer. Methods: Both polymorphisms were evaluated by RFLP — PCR in blood samples obtained from 117 women with sporadic breast cancer. Patients were stratified by genotype, Bloom — Richardson grade, TNM stage, estrogene and progesterone receptors (PR) status and the linkages of each genotype with each stratum were calculated by logistic regression. Results: Variant genotypes and alleles of both polymorphisms of the BRCA2 gene were inversely related to hormone receptor status for a group of patients with at least one positive receptor status as compared to a group with both receptors negative status (OR 0.27, 95% CI 0.07 — 0.95, p = 0.043 and OR 0.39, 95% CI 0.19 — 0.82, p = 0.013 for Met1915Met homozygote and 1915Met allele, respectively and OR 0.02, 95% CI 0.00 — 0.13, p = 0.0005 and OR 0.43, 95% CI 0.21 — 0.88, p = 0.021, for Val784Val homozygote and the 784Val allele. No association was found between both polymorphisms and Bloom — Richardson grading and TNM staging. Conclusions: Our results suggest that variant genotypes of the Thr1915Met and Met784Val polymorphisms of the BRCA2 gene may be indicative factors in therapy of ductal breast cancer.

Key Words: breast cancer, BRCA2, DNA repair, gene polymorphism

Language:  English

[full text]




Copyright (c) MORION 1999-2008

Current issue | Archive | subscribe | Instructions to Authors | E-Mail to webmaster